



## Syndax Announces Participation at Three Upcoming Investor Conferences

September 2, 2021

WALTHAM, Mass., Sept. 2, 2021 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that members of its management team will participate in three upcoming virtual investor conferences:

- A fireside chat at the Morgan Stanley 19th Annual Global Healthcare Conference at 9:30 a.m. ET on Thursday, September 9, 2021.
- A panel at the Citi 16th Annual BioPharma Virtual Conference at 9:45 a.m. ET on Friday, September 10, 2021.
- A fireside chat at the Baird Global Healthcare Conference at 8:30 a.m. ET on Tuesday, September 14, 2021.

A live webcast of the Morgan Stanley presentation and Citi panel can be accessed from the Investor section of the Company's website at [www.syndax.com](http://www.syndax.com), where a replay of the events will also be available for a limited time.

### About Syndax Pharmaceuticals, Inc.

Syndax Pharmaceuticals is a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies. The Company's pipeline includes SNDX-5613, a highly selective inhibitor of the Menin-MLL binding interaction, axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1 (CSF-1) receptor, and entinostat, a class I HDAC inhibitor. For more information, please visit [www.syndax.com](http://www.syndax.com) or follow the Company on [Twitter](#) and [LinkedIn](#).

### Syndax Contacts

Investor Contact  
Melissa Forst  
Argot Partners  
[melissa@argotpartners.com](mailto:melissa@argotpartners.com)  
Tel 212.600.1902

Media Contact  
Ted Held  
[ted.held@gcihealth.com](mailto:ted.held@gcihealth.com)  
Tel 212.798.9842

SNDX-G

 View original content: <https://www.prnewswire.com/news-releases/syndax-announces-participation-at-three-upcoming-investor-conferences-301368070.html>

SOURCE Syndax Pharmaceuticals, Inc.